ArticleScientific reports2025
Delphinidin upregulates microRNA-let-7b expression through family with sequence similarity 222 member B.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting cancer with delphinidin: from molecular insights to therapeutic implications.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Delphinidin is a major anthocyanidin belonging to the flavonoid family with pharmacological activities against cancer, inflammation, and muscle atrophy. However, the mechanism regulating its activity is yet to be completely elucidated. The present study aimed to identify the molecules responsible for the effects of delphinidin. We investigated the effects of delphinidin on melanoma cells and observed that delphinidin upregulates the expression of let-7b, a microRNA (miRNA) that inhibits the proliferation of melanoma cells. Delphinidin-induced upregulation of let-7b led to the suppression of cyclin D1, a target gene associated with cell cycle progression. Using genetic functional screening, we identified that family with sequence similarity 222 member B (Fam222B) is an important factor behind the inhibitory effects of delphinidin against melanoma cell proliferation and that the transfection with small interfering RNA specifically targeting Fam222B altered miRNAs expression in B16 cells. In summary, delphinidin exerts antimelanoma effects by increasing let-7b expression through Fam222B, and Fam222B is involved in regulating miRNA expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.